IOVA Iovance Biotherapeutics Inc.

41
+2.85  (+7%)
Previous Close 38.15
Open 38.23
Price To Book 21.35
Market Cap 5,201,324,780
Shares 126,861,580
Volume 1,453,775
Short Ratio
Av. Daily Volume 1,878,677
Stock charts supplied by TradingView

NewsSee all news

  1. Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma

    Median Duration of Response Not Reached at 17.0 Months of Median Study Follow Up in C-144-01 Study Oral Presentation to Include Additional Cohort 2 Data from C-144-01 Clinical Study at ASCO 2020 Virtual Scientific

  2. Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

    SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte,

  3. Iovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific Program

    SAN CARLOS, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that new

  4. Frazier Healthcare Partners Adds Experienced Capital Markets Executive to Life Sciences Team

    Frazier Healthcare Partners announced David Topper has joined the Life Sciences team as a Senior Advisor. He has over 35 years of experience in the capital markets. Mr. Topper was formerly the global head of capital

  5. Iovance Biotherapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, May 5, 2020

    SAN CARLOS, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initiated March 2017. Poster session at SITC November 10, 2017. Data released January 24, 2018 showed 3/8 PRs.
LN-145
Head and neck cancer
Phase 2 new interim data to be presented at ASCO May 29, 2020.
LN-144 - lifileucel (ASCO)
Refractory metastatic melanoma
Phase 2 data released May 31, 2019 noted ORR 44%; CR 11%. Top-line data due 2020.
LN-145
Cervical cancer
Phase 1 data presented at AACR Virtual Annual Meeting April 28, 2020.
Tumor infiltrating lymphocytes (TIL)
Non-small cell lung cancer (NSCLC)

Latest News

  1. Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma

    Median Duration of Response Not Reached at 17.0 Months of Median Study Follow Up in C-144-01 Study Oral Presentation to Include Additional Cohort 2 Data from C-144-01 Clinical Study at ASCO 2020 Virtual Scientific

  2. Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

    SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte,

  3. Iovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific Program

    SAN CARLOS, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that new

  4. Frazier Healthcare Partners Adds Experienced Capital Markets Executive to Life Sciences Team

    Frazier Healthcare Partners announced David Topper has joined the Life Sciences team as a Senior Advisor. He has over 35 years of experience in the capital markets. Mr. Topper was formerly the global head of capital

  5. Iovance Biotherapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, May 5, 2020

    SAN CARLOS, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter

  6. Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020

    SAN CARLOS, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that H. Lee

  7. Iovance Biotherapeutics to Present at Upcoming Conferences

    SAN CARLOS, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the

  8. Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

    SAN CARLOS, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte,

  9. Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020

    SAN CARLOS, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter

  10. Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

    SAN CARLOS, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the

  11. Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel

    - Biologics Licensing Application (BLA) submission planned for late 2020 - SAN CARLOS, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company

  12. Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog

    SAN CARLOS, Calif., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the

  13. Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

    SAN CARLOS, Calif. and NEW YORK, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis

  14. Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December

    SAN CARLOS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the

  15. Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy

    -  41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy -             - Median duration of response (DOR) was not reached as assessed

  16. Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting

    - Cohort 2 objective response rate (ORR) as determined by independent review committee (IRC) was 35 percent, which aligns well with the investigator assessed ORR of 36 percent - - Median duration of response (DOR)

  17. Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November

    SAN CARLOS, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL)

  18. Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results

                - Late-breaking abstract at Society for Immunotherapy of Cancer (SITC) meeting to feature Independent Review Committee (IRC) read results from Cohort 2 of C-144-01 melanoma trial -                         -

  19. Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019

    SAN CARLOS, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL)

  20. Iovance Biotherapeutics to Present at Upcoming Conferences

    SAN CARLOS, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte

  21. Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September

    SAN CARLOS, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL)